Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Alice has learned to generate texts with YandexGPT

5/17/23 YNDX

SPB Exchange will create a secure chain of securities from Hong Kong by the end of the year

5/17/23 SPBE

Tencent reported 3 months of 2023

5/17/23 700

Board of Directors of IDGC of Urals recommended that dividends be paid for 2022

5/17/23 MRKU

Fix Price entered the Armenian market

5/17/23 FIXP

Alrosa resumed work at the Zarya pipe

5/16/23 ALRS

HeadHunter Group reported for 3 months of 2023

5/16/23 HEAD

Binnopharm Group will open a representative office in China by the end of May

5/16/23 AFKS

Shareholders of TNS Energy Kuban approved dividends for 2022

5/16/23 KBSB

Shareholders of RosDorBank approved dividends for 2022

5/16/23 RDRB